Want to see IL:NRGN full AI Analyst Report?
NRGN Stock Chart & Stats
139.30
0.03(0.96%)
At close: 4:00 PM EST
139.30
0.03(0.96%)
Day’s Range― - ―
52-Week Range111.00 - 305.90
Previous CloseN/A
Volume1.26K
Average Volume (3M)7.79K
Market Cap
₪15.10M
Enterprise Value5.76M
Total Cash (Recent Filing)₪3.18M
Total Debt (Recent Filing)₪145.02K
Price to Earnings (P/E)―
Beta0.55
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding13,327,785
10 Day Avg. Volume12,535
30 Day Avg. Volume7,787
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.94
Price to Sales (P/S)2.64
P/FCF Ratio116.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue ReboundThe sharp 2025 revenue rebound shows renewed commercial traction after several years of contraction. If the improvement persists, a larger customer and project base could provide operating leverage and support investment in the Genomics Suite and related services.
Gross Margin ImprovementThe substantial gross-margin expansion indicates improved economics on delivered software and genomics work. A higher gross-profit base can strengthen the company’s ability to fund product development, customer support, and sales while reducing the revenue needed to approach breakeven.
Conservative LeverageVery low debt relative to equity limits interest burden and preserves financial flexibility. This gives Nrgene more capacity to absorb uneven operating performance and fund its genomics platform without the immediate constraints associated with a heavily leveraged balance sheet.
Bears Say
Persistent Operating LossesDespite stronger revenue and gross margin, Nrgene remains deeply loss-making at both net and operating levels. Continued losses weaken retained capital and show that the current scale and cost structure have not yet produced sustainable earnings power.
Unproven Free-cash-flow DurabilityThe return to slightly positive free cash flow is encouraging but remains too small and volatile to establish a durable self-funding model. Prior cash burn and the sharp year-over-year decline leave ongoing execution and cash-conversion risk over the coming periods.
Negative Shareholder ReturnsNegative return on equity reflects that the business is not currently generating value from its capital base. Historical equity volatility, including a prior negative-equity period, adds concern that continued losses could erode financial resilience even with low current leverage.
NRGN FAQ
What was NRGENE TECHNOLOGIES LTD’s price range in the past 12 months?
NRGENE TECHNOLOGIES LTD lowest stock price was 111.00 and its highest was 305.90 in the past 12 months.
What is NRGENE TECHNOLOGIES LTD’s market cap?
NRGENE TECHNOLOGIES LTD’s market cap is ₪15.10M.
When is NRGENE TECHNOLOGIES LTD’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were NRGENE TECHNOLOGIES LTD’s earnings last quarter?
Currently, no data Available
Is NRGENE TECHNOLOGIES LTD overvalued?
According to Wall Street analysts NRGENE TECHNOLOGIES LTD’s price is currently Overvalued.
Does NRGENE TECHNOLOGIES LTD pay dividends?
NRGENE TECHNOLOGIES LTD does not currently pay dividends.
What is NRGENE TECHNOLOGIES LTD’s EPS estimate?
NRGENE TECHNOLOGIES LTD’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NRGENE TECHNOLOGIES LTD have?
NRGENE TECHNOLOGIES LTD has 13,327,785 shares outstanding.
What happened to NRGENE TECHNOLOGIES LTD’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NRGENE TECHNOLOGIES LTD?
Currently, no hedge funds are holding shares in IL:NRGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NRGENE TECHNOLOGIES LTD
NRGene Technologies Ltd is an AI-powered genomics firm that designs sophisticated computational tools and advanced algorithms, serving clients globally across North America, Europe, the Middle East, Africa, and Asia Pacific. The company provides specialized software applications and complete, ready-to-use solutions for various sectors, including agricultural breeding, food technology, academia, research institutions, and agribiotech enterprises. Additionally, NRGene develops custom genetic panels tailored for a broad range of plants, from staple crops like wheat, canola, corn, soybeans, and maize to cannabis. Established in 2009, its headquarters are located in Ness Ziona, Israel.